Anavex Life Sciences Reports Promising Results for Parkinson’s Disease Treatment
Anavex Life Sciences has announced promising data from its 48-week open-label extension study, highlighting the potential of their lead drug candidate, ANAVEX®2-73 (blarcamesine), in treating Parkinson’s disease dementia. The study demonstrated that ANAVEX®2-73 showed significant clinical benefits, achieving both primary and secondary objectives over the trial period. ANAVEX®2-73 is an oral small-molecule activator of the […]